Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H19N2O2.Br |
| Molecular Weight | 303.195 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
InChI
InChIKey=LULNWZDBKTWDGK-UHFFFAOYSA-M
InChI=1S/C12H19N2O2.BrH/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;/h6-9H,1-5H3;1H/q+1;/p-1
| Molecular Formula | C12H19N2O2 |
| Molecular Weight | 223.2915 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB01400Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction. Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
69.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
79.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.5 h |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75% |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | yes (co-administration study) Comment: information obtained from abstract: AUC of coadministered drug, parathion, parathion was significantly greater than control (65.1 versus 74.3 microg min/ml) |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Myasthenia gravis syndrome associated with trimethadione. | 1970 Jun 29 |
|
| Thioridazine toxicity. Agranulocytosis and hepatitis with encephalopathy. | 1973 Apr 23 |
|
| Train-of-four nerve stimulation in the management of prolonged neuromuscular blockade following succinylcholine. | 1975 Jan |
|
| Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. | 1977 |
|
| Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
| Impairment of the antagonism of vecuronium-induced paralysis and intra-operative disopyramide administration. | 1989 Jan |
|
| Acetylcholinesterase fiber-optic biosensor for detection of anticholinesterases. | 1991 May |
|
| Reversal of antihypertensive agent-induced postural hypotension with physostigmine. | 1991 May-Jun |
|
| Effects of adrenergic blockers on central nervous system-mediated hyperglycemia in fed rats. | 1992 May |
|
| Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. | 1996 Aug |
|
| International Association for the Study of Pain--Ninth World congress. 22-27 August 1999, Vienna, Austria. | 1999 Nov |
|
| Sex differences in cholinergic analgesia II: differing mechanisms in two models of allodynia. | 1999 Nov |
|
| The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
| [Slow channel syndrome due to an autosomal translocation at 2q31-9p27]. | 2002 May |
|
| Masseter muscle spasm following atracurium. | 2004 May |
|
| [Myasthenia in elderly patients: a series of 23 cases]. | 2005 Dec |
|
| A conscious mouse model of gastric ileus using clinically relevant endpoints. | 2005 Jun 6 |
|
| Sphincter of Oddi and its dysfunction. | 2008 Jan |
|
| Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. | 2008 Jan |
|
| Prucalopride: the evidence for its use in the treatment of chronic constipation. | 2008 Jun |
|
| Myasthenia gravis and autoimmune Addison disease in a patient with thymoma. | 2009 Sep |
Patents
Sample Use Guides
The recommended dose range of Neostigmine Methylsulfate Injection is 0.03 mg/kg to 0.07 mg/kg administered as an intravenous bolus.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:12:33 UTC 2023
by
admin
on
Fri Dec 15 15:12:33 UTC 2023
|
| Record UNII |
005SYP50G5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9041075
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
757233
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
114-80-7
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
DBSALT001191
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
82055
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
204-054-8
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
401
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
NEOSTIGMINE BROMIDE
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Very soluble in water; freely soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cholinergic. Storage: Neostigmine bromide should be kept in a tightly closed container, protected from light. Definition: Neostigmine bromide contains not less than 98.0% and not more than 101.0% of C12H19BrN2O2, calculated withreference to the dried substance. | ||
|
1459001
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
8246
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
005SYP50G5
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL278020
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
m7819
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000092016
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
C76612
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
179557
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY | |||
|
SUB09195MIG
Created by
admin on Fri Dec 15 15:12:33 UTC 2023 , Edited by admin on Fri Dec 15 15:12:33 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
IMPURITY (UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |